IP Library Granted Patent US 8,426,465
Granted Patent B2
US 8,426,465 · App. 13/302,988 · Granted Apr 23, 2013

Substituted acylanilides and methods of use thereof

Inventors: James T. Dalton (Lakeland, TN); Duane D. Miller (Germantown, TN)
Assignee: University of Tennesse Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,426,465
App. No.
13/302,988
Granted
Apr 23, 2013
Kind
B2
Abstract

This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.

Claims (21)

1. A pharmaceutical composition for contraception in a male subject, comprising the compound represented by the structure of formula (I):

or its isomer or pharmaceutically acceptable salt.

2. A method of hormone therapy comprising the step of contacting an androgen receptor of a subject with compound represented by the structure of formula (I):

or its isomer or pharmaceutically acceptable salt.

3. A method of treating, reducing the severity of, reducing the incidence of, delaying the onset of, or reducing pathogenesis of diabetes in a human subject, comprising the step of administering an effective amount of the compound represented by the structure of formula (I):

or its isomer or pharmaceutically acceptable salt, to said subject.

4. A method of treating, reducing the severity of, reducing the incidence of, delaying the onset of, or reducing pathogenesis of glucose intolerance in a human subject, comprising the step of administering an effective amount of the compound represented by the structure of formula (I):

or its isomer or pharmaceutically acceptable salt, to said subject.

5. A method of treating, reducing the severity of, reducing the incidence of, delaying the onset of, or reducing pathogenesis of hyperinsulinemia in a human subject, comprising the step of administering an effective amount of the compound represented by the structure of formula (I):

or its isomer or pharmaceutically acceptable salt, to said subject.

6. A method of treating, reducing the severity of, reducing the incidence of, delaying the onset of, or reducing pathogenesis of insulin resistance in a human subject, comprising the step of administering an effective amount of the compound represented by the structure of formula (I):

or its isomer or pharmaceutically acceptable salt, to said subject.

7. A method of treating, reducing the severity of, reducing the incidence of, delaying the onset of, or reducing pathogenesis of diseases associated with diabetes comprising the step of administering an effective amount of the compound represented by the structure of formula (I):

or its isomer or pharmaceutically acceptable salt, to said subject.

8. A method of treating, reducing the severity of, reducing the incidence of, delaying the onset of, or reducing pathogenesis of fatty liver conditions in a human subject, comprising the step of administering an effective amount of the compound represented by the structure of formula (I):

or its isomer or pharmaceutically acceptable salt, to said subject.

9. A method of treating, reducing the severity of, reducing the incidence of, delaying the onset of, or reducing pathogenesis of cardiovascular disease in a human subject, comprising the step of administering an effective amount of the compound represented by the structure of formula (I):

or its isomer or pharmaceutically acceptable salt, to said subject.

10. A method of treating a disease or condition of the eye of a subject, comprising the step of administering an effective amount of a compound represented by the structure of formula (I):

or its isomer or pharmaceutically acceptable salt, to said subject.

11. The method of claim 10 , wherein the disease or condition is selected from the group consisting of Sjogren's syndrome, or xerophthalmia.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2012
From: DALTON, JAMES T.; MILLER, DUANE D.
To: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Reel/Frame 027575/0198 →
Continuity (4)
Division 11892595 · Aug 24, 2007
Provisional Application 60839665 · Aug 24, 2006
Provisional Application 60907749 · Apr 16, 2007
Related Publication 20120136052A1 · May 31, 2012